Esperion Therapeutics | ESPR - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.89B 415M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Cipla INR 41.64B 6.31B 2025-12
CSL USD 4.46B 2.71B 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Geron USD 46.71M 525K 2025-12
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 243M 48M 2026-03
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Pfizer USD 12.28B 8.74B 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12